These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 32567995)

  • 41. An
    Havranek B; Islam SM
    J Biomol Struct Dyn; 2021 Aug; 39(12):4304-4315. PubMed ID: 32544024
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Understanding the binding affinity of noscapines with protease of SARS-CoV-2 for COVID-19 using MD simulations at different temperatures.
    Kumar D; Kumari K; Jayaraj A; Kumar V; Kumar RV; Dass SK; Chandra R; Singh P
    J Biomol Struct Dyn; 2021 Apr; 39(7):2659-2672. PubMed ID: 32362235
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A computational study on active constituents of
    Shamsi S; Anjum H; Shahbaaz M; Khan MS; Ataya FS; Alamri A; Alhumaydhi FA; Husain FM; Rehman MT; Mohammad T; Islam A; Anjum F; Shamsi A
    J Biomol Struct Dyn; 2022 Oct; 40(17):7702-7713. PubMed ID: 33759703
    [TBL] [Abstract][Full Text] [Related]  

  • 44.
    Mohapatra PK; Chopdar KS; Dash GC; Mohanty AK; Raval MK
    J Biomol Struct Dyn; 2023 Feb; 41(2):435-444. PubMed ID: 34821198
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structural basis for the inhibition of SARS-CoV2 main protease by Indian medicinal plant-derived antiviral compounds.
    Saravanan KM; Zhang H; Senthil R; Vijayakumar KK; Sounderrajan V; Wei Y; Shakila H
    J Biomol Struct Dyn; 2022 Mar; 40(5):1970-1978. PubMed ID: 33073712
    [TBL] [Abstract][Full Text] [Related]  

  • 46. On the search for COVID-19 therapeutics: identification of potential SARS-CoV-2 main protease inhibitors by virtual screening, pharmacophore modeling and molecular dynamics.
    Hassan A; Arafa RK
    J Biomol Struct Dyn; 2022 Oct; 40(17):7815-7828. PubMed ID: 33749545
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chetomin, a SARS-CoV-2 3C-like Protease (3CL
    Ibrahim MAA; Abdelrahman AHM; Mohamed DEM; Abdeljawaad KAA; Naeem MA; Gabr GA; Shawky AM; Soliman MES; Sidhom PA; Paré PW; Hegazy MF
    Viruses; 2023 Jan; 15(1):. PubMed ID: 36680290
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Screening of potent phytochemical inhibitors against SARS-CoV-2 protease and its two Asian mutants.
    Muhammad I; Rahman N; Gul-E-Nayab ; Niaz S; Basharat Z; Rastrelli L; Jayanthi S; Efferth T; Khan H
    Comput Biol Med; 2021 Jun; 133():104362. PubMed ID: 33894500
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of potential SARS-CoV-2 M
    Sobhia ME; Ghosh K; Sivangula S; Kumar S; Singh H
    J Biomol Struct Dyn; 2022 Jul; 40(11):5079-5089. PubMed ID: 33413032
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of the effects of chlorhexidine and several flavonoids as antiviral purposes on SARS-CoV-2 main protease: molecular docking, molecular dynamics simulation studies.
    Tatar G; Salmanli M; Dogru Y; Tuzuner T
    J Biomol Struct Dyn; 2022 Oct; 40(17):7656-7665. PubMed ID: 33749547
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined drug repurposing and virtual screening strategies with molecular dynamics simulation identified potent inhibitors for SARS-CoV-2 main protease (3CLpro).
    Khan A; Ali SS; Khan MT; Saleem S; Ali A; Suleman M; Babar Z; Shafiq A; Khan M; Wei DQ
    J Biomol Struct Dyn; 2021 Aug; 39(13):4659-4670. PubMed ID: 32552361
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study.
    Das S; Sarmah S; Lyndem S; Singha Roy A
    J Biomol Struct Dyn; 2021 Jun; 39(9):3347-3357. PubMed ID: 32362245
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    Erdogan T
    J Biomol Struct Dyn; 2023 Apr; 41(6):2448-2465. PubMed ID: 35088655
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cyanobacterial metabolites as promising drug leads against the M
    Naidoo D; Roy A; Kar P; Mutanda T; Anandraj A
    J Biomol Struct Dyn; 2021 Oct; 39(16):6218-6230. PubMed ID: 32691680
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular docking and simulation studies on SARS-CoV-2 M
    Lokhande KB; Doiphode S; Vyas R; Swamy KV
    J Biomol Struct Dyn; 2021 Nov; 39(18):7294-7305. PubMed ID: 32815481
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Investigating the novel acetonitrile derivatives as potential SARS-CoV-2 main protease inhibitor using molecular modeling approach.
    Patil AF; Patil VS; Jaiswal DP; Palakhe SS; Patil SP; Kumbhar BV
    J Biomol Struct Dyn; 2023 Jun; 41(9):3943-3955. PubMed ID: 35382699
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reporting dinaciclib and theodrenaline as a multitargeted inhibitor against SARS-CoV-2: an
    Ahmad S; Pasha Km M; Raza K; Rafeeq MM; Habib AH; Eswaran M; Yadav MK
    J Biomol Struct Dyn; 2023 Jun; 41(9):4013-4023. PubMed ID: 35451934
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease.
    Batool F; Mughal EU; Zia K; Sadiq A; Naeem N; Javid A; Ul-Haq Z; Saeed M
    J Biomol Struct Dyn; 2022 May; 40(8):3777-3788. PubMed ID: 33251983
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacophore based virtual screening, molecular docking, molecular dynamics and MM-GBSA approach for identification of prospective SARS-CoV-2 inhibitor from natural product databases.
    Kumar BK; Faheem ; Sekhar KVGC; Ojha R; Prajapati VK; Pai A; Murugesan S
    J Biomol Struct Dyn; 2022 Feb; 40(3):1363-1386. PubMed ID: 32981461
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potential of NO donor furoxan as SARS-CoV-2 main protease (M
    Al-Sehemi AG; Pannipara M; Parulekar RS; Patil O; Choudhari PB; Bhatia MS; Zubaidha PK; Tamboli Y
    J Biomol Struct Dyn; 2021 Sep; 39(15):5804-5818. PubMed ID: 32643550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.